A study in Cancer Discovery proposes that a blood-based approach combining circulating tumor DNA and immune cell readouts can identify cancer neoantigens and reactive T cells without a tissue biopsy. Reported performance largely matches, and in some settings exceeds, what standard tumor testing reveals, positioning the platform as a potential bridge for selecting and monitoring personalized immunotherapy.